enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update
1. Q2 cash burn at $3.8 million aligns with projections, funding through Q3'2026. 2. Phased launch of VenoValve® and enVVe® IDE submission expected by 2H'2025.